Pfizer says COVID-19 vaccine for kids 5-11 was over 90% effective in trials, appears safe
CBSN
Two doses of Pfizer's COVID-19 vaccine adjusted in potency for children 5 to 11 years old proved 90.7% effective against symptomatic disease, the company said in documents filed with the government, as U.S. authorities near key decisions on whether to expand use of the shots to younger age groups.
The estimate comes from early results of the company's trials of the vaccine in more than 2,000 participants from 5 to 11 years old, which were released Friday as part of the company's submission to the Food and Drug Administration's outside vaccine advisers.
The advisers are scheduled to meet on Tuesday next week to weigh in on whether the FDA should grant emergency use authorization for the shots in younger American children. Currently, Pfizer's vaccine is only permitted for use in adolescents 12 years and older.
